Anti-cancer mechanisms of indirubin-3'-monoxime by SHI JIE
  





 SHI JIE 





A THESIS SUBMITTED 
FOR THE DEGREE OF MASTER OF SCIENCE 
 
DEPARTMENT OF COMMUNITY, OCCUPATIONAL AND FAMILY 
MEDICINE,  
YONG LOO LIN SCHOOL OF MEDICINE 





I would like to express my deepest respect and acknowledgements to my 
supervisor, Associate Prof. Shen Han-Ming, for his consistent and invaluable 
guidance throughout my M.Sc. study. He is the person who always encourages me, 
provides professional comments and guides me to the right way of doing scientific 
research. What I have learned from him will benefit my career and life. 
I would also like to extend my sincere gratitude and appreciation to: 
Prof Ong Choon Nam for his kind comments and support 
Prof. David Koh, Head of the department, for his general kind support during 
the course of this study. 
Mr. Ong Her Yam, Mr. Ong Yeong Bing, Ms Su Jin and Ms Zhao Min for 
their kind help in the process of laboratory work. 
Dr. Shi Ranxin, Dr. Huang Qing, Dr. Zhang Siyuan, Dr. Luo Guodong, and 
Ms Zhou Jing for their critical discussions, invaluable comments and consistent help 
during whole course of my study. 
Dr. Lai Jiaping and Dr. Ong Eng Shi, for their critical comments on the 
project. 
All other staff in Department, for their general and unselfish help. 
National University of Singapore, for the research scholarship 
Especially, I would like express my deepest appreciation to my family 
members and friends for their love, understanding and support.  
 ii
TABLE OF CONTENTS 
 
Title page               i 
Acknowledgements             ii 
Table of contents            iii 
Summary            vii 
List of Publications          viii 
List of Figures             ix 
List of Tables             xi 
List of Abbreviations           xii 
 
1 Chapter 1 Introduction           1 
1.1 Indirubin and its derivatives          2 
1.1.1 General introduction           2 
1.1.2 Chemical structures and purification         4 
1.1.3 Cellular absorption and metabolism         5 
1.2 Pharmacological mechanisms of Indirubin and it derivatives      5 
1.2.1 Anti-inflammatory activity          5 
1.2.2 Anti-cancer activity           6 
1.2.2.1 Clinical trials           7 
1.2.2.2 In vitro experimental evidence         7 
1.2.2.2.1 Cell cycle           8 
1.2.2.2.2 Cytotoxicity        11 
1.2.2.2.3 Sensitization        13 
1.2.2.2.4 Anti-angiogenesis       14 
 iii
1.2.2.3 In vivo Animal Model        16 
1.2.3 Molecular targets of I3M        16 
1.2.3.1 Cyclin-dependent kinase (CDK)      16 
1.2.3.2 Src kinase and Stat3 signalling pathway      18 
1.2.3.3 Aryl hydrocarbon receptor (AhR)      18 
1.2.3.4 Glycogen synthetase kinase-3 (GSK3)      19 
1.2.3.5 c-Jun NH2-terminal kinase (JNK)      20 
1.2.3.6 Fibroblast growth factor receptor 1 (FGFR1)     20 
1.3 Apoptosis           21 
1.3.1 General introduction         21 
1.3.2 Apoptosis pathways         22 
1.3.2.1 Receptor-mediated apoptosis       25 
1.3.2.2 Mitochondrial-mediated apoptosis      27 
1.3.2.3 Type I and type II cells        28 
1.3.3 Bcl-2 family          28 
1.3.4 Other regulatory mechanisms        30 
1.3.5 Apoptosis and cancer         30 
1.3.6 TRAIL signaling pathway as potential therapeutic target    32 
1.4 Objectives of the study         33 
                                                                           
Chapter 2 Materials and Methods        34 
2.1 Reagents, chemicals and plasmids       35 
2.2 Cell culture          35 
2.3 Growth inhibition test: MTT        36 
2.4 Western blot          36 
 iv
2.5 Detection of apoptosis         37 
2.5.1 DAPI staining          37 
2.5.2 PI staining followed by flow cytometry      37 
2.6 Measurement of caspase activity       38 
2.7 Measurement of surface expressions of death receptors    38 
2.8 Transfection          39 
2.8.1 Transient transfection of siRNA       39 
2.8.2 Stable transfection of vectors expressing Bid siRNA     39 
2.8.3 Detection of Bcl-2 or CrmA transfected cells using flow cytometry   40 
2.9 Detection of Bax conformational change      40 
2.9.1 Immunofluorescence         40 
2.9.2 Immunoprecipitation         41 
2.10 Subcellular fractionation         42 
2.11 Long-term clonogenic assay        42 
2.12 Statistical analysis         42 
                                                                           
Chapter 3 Results          44 
3.1 I3M induces apoptosis in a time- and dose-dependent manner in 
human cancer cells         45 
3.2 I3M leads to caspase activation        45 
3.3 I3M induces increased surface expression of death receptors 
accompanying p53 up-regulation      51 
3.4 I3M causes Bid cleavage        55 
3.5 I3M induces Bax conformational changes     59 
3.6 I3M induces cytochrome c release      63 
 v
3.7 Overexpression of Bcl-2 or CrmA partially blocks I3M-induced 
apoptosis           63 
3.8 I3M sensitizes cancer cells to TRAIL–induced apoptosis    68 
 
Chapter 4 Discussions and conclusions        72 
4.1 I3M induce apoptosis in HeLa, HepG2 and HCT116     73 
4.2 Apoptosis induced by I3M recruits extrinsic pathways with type II 
response           74 
4.3 Critical role of pro-apoptotic Bcl-2 family members     77 
4.4 Sensitization of TRAIL-induced apoptosis      78 
4.5 Conclusions          79 
4.6 Directions for future study        79 
                                                                               




Indirubin-3’-monoxime (I3M) is a derivative of indirubin, an active 
component from a Chinese medicinal recipe for the treatment of leukemia. Indirubin 
and its derivatives, a group of bis-indole alkaloid, have exhibited strong growth 
inhibitory effects on various human cancer cells. In the attempt to reveal the 
mechanism of action of indirubins, various biological activities of indirubin and its 
derivatives have been discovered. To investigate the anti-cancer effect of I3M, a study 
was done to evaluate the apoptotic machinery involved by focusing on the role of the 
pro-apoptotic Bcl-2 family members in I3M-induced apoptotic cell death. 
 First, the cytotoxicity of I3M in three different types of human cancer cells 
was confirmed — cervical cancer-HeLa, hepatoma-HepG2 and colon cancer-HCT116 
through flow cytometry analysis (after propidium iodide staining) and MTT assays. 
I3M -induced apoptosis was detected in a time- and dose-dependent manner in 
the above mentioned human cancer cells, based on 4',6-diamidino-2-phenylindole 
(DAPI) staining, flow cytometry analysis and PARP cleavage. Caspase-8, caspase-9 
and caspase-3 cleavage were observed in I3M-induced apoptosis in HeLa. Caspase 
3/7 activity in the three cell lines was also measured. The participation of various 
caspases in I3M-induced apoptosis was examined by using respective synthetic 
inhibitors. 
An increased surface expression level of death receptor 4 and 5 (DR4 and 
DR5) was detected in HeLa cells. A time-dependent increase in the total protein level 
of DR4 and DR5 was also observed. Interestingly, concurrent up-regulation of p53 
protein level and its transcriptional activity as indicated by increased p21 correlated 
 vii
with the up-regulation of DR4 and DR5, suggesting an important role of p53 in the 
initiation of the death receptor pathway. 
One important observation was that caspase-8 activation resulted in Bid 
cleavage, followed by Bax conformational change, and cytochrome c release. Stable 
knockdown of Bid partially protected I3M-induced apoptosis by blocking Bax 
conformational change. Also, transient overexpression of a viral caspase inhibitor 
(CrmA) or Bcl-2 partially protected I3M-induced apoptosis. 
Furthermore, I3M was shown to sensitize TNF-related apoptosis-inducing 
ligand (TRAIL)-induced apoptosis in human cancer cell lines according to flow 
cytometry analysis, DAPI staining, and long-term colony formation assay. 
In conclusion, I3M-induced apoptosis was found to engage both extrinsic and 
intrinsic pathways involving the pro-apoptotic Bcl-2 family members (Bid and Bax) 
which play a critical role. In addition, there was evidence showing the sensitizing 
effect of I3M on TRAIL-induced apoptosis, which will form the basis of future 
studies. 
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Chapter 1 Introduction 
1.1 Indirubin and its derivatives 
1.1.1 General introduction 
Scientific interest on indirubin originated from its role as an anti-leukemia agent, the 
active component of a traditional Chinese medicine preparation Danggui Longhui Wan, 
which has been used in China for the treatment of various chronic diseases for 
centuries (Eisenbrand et al., 2004; Xiao et al., 2002). Out of the 11 herbal constituents, 
Qing Dai (Indigo naturalis) was initially characterized as the active ingredient, a dark 
blue mixture isolated from the leaves of Baphicacanthus cusia (Acanthaceae), 
Polygonum tinctorium (Polygonaceae), Isatis indigotica (Brassicaceae), Indigofera 
suffrutticosa (Fabaceae) and Indigofera tinctoria (Fabaceae)(Hoessel et al., 1999) (Fig. 
1.1A). Although a high level of indigo (blue dye) is present in the mixture, the anti-
leukemic activity was attributed to the presence of red-coloured 3,2’-isomer indirubin 
(Wu and Fang, 1980; Zhang et al., 1979a; Zhang et al., 1979b; Zhang, 1983). 
Indirubin and its derivatives have exhibited strong growth inhibitory effects on various 
human cancer cells, manifested by either cell cycle arrest (G2/M) (Hoessel et al., 1999; 
Yamaguchi et al., 2002) or cytotoxicity (mainly apoptosis) (Nam et al., 2005; Perabo 
et al., 2006; Ribas et al., 2006; Yamaguchi et al., 2002). An in vivo study carried out in 
rat tumor model provides further evidence for indirubins’ anti-tumor activity (Kim et 
al., 2007). In the attempt to reveal the mechanism of action of indirubins, various 
biological activities of indirubin and its derivatives have been discovered. It has been 
well established that indirubin and indirubin-3’-monoxime (I3M) are strong inhibitors 
for cyclin-dependent kinases (CDKs) (Hoessel et al., 1999; Perabo et al., 2006). In 
addition, there is evidence suggesting that indirubin and I3M inhibit glycogen 
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Figure 1.1  Qing Dai and chemical structures of indirubin derivatives. A. Photos of 
Indigo naturalis and indigo blue. B. Chemical structures of indigo, indirubin and 




thase kinase-3ß (GSK-3ß) (Leclerc et al., 2001; Meijer et al., 2003), and c-Src 
inase (Stat3 signalling) (Nam et al., 2005), but activate aryl hydrocarbon receptor 
(AhR), a co-transcriptional factor (Adachi et al., 2001). It was reported that indirubin 
could suppress the nuclear factor kappa B (NF-κB) activation and hence sensitize 
tumor necrosis factor (TNF)-induced apoptosis (Sethi et al., 2006). More recently, I3M 
has been found to inhibit autophosphorylation of FGFR1 and stimulate ERK1/2 
activity through long-term p38 MAPK activation (Zhen et al., 2007). 
 
1.1.2 Chemical structure and purification  
Indirubin and its derivatives are a group of bis-indole alkaloid with their chemical 
structures shown in Fig. 1.1B. The presence of indirubin in the mixture prepared from 
Qing Dai is minute (0.11%)(Xiao et al., 2002); therefore synthesis of indirubin is 
required. Indirubin (also known as isoindigotin or indigo red) can be derived by 
oxidation and spontaneous dimerization of indoxyl and isatin, which are in turn 
derived from precursor conjugates in naturally occuring isatan B (from Isatis tinctoria) 
or indican (from Indigofera and Polygonum); the detailed process has been described 
by Meijer et al. in 1999. Due to the poor solubility of indirubin, indirubin-3’-
monoxime (I3M), a derivative of indirubin, is purchased from Sigma and studied in the 
project. 
Besides extraction from indigo dye-producing plants with more than 200 species, 
indirubin is also present in another dye ‘Tyrean purple’, which can be produced from 
more than 15 species of Muricidae mollusks (Meijer et al., 2003). In addition, certain 
wild-type and recombinant bacteria can also synthesize indirubin (with reference to 
Wu et al. 2005). Under pathological conditions including leukemia, indirubin can be 
detected in human urine, which can be explained by the metabolism of tryptophan into 
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indole, followed by further oxidization process in the liver, and ultimate 
decomposition to indirubin by bacteria (Hoessel et al., 1999). 
 
1.1.3 Cellular absorption and metabolism 
So far only very limited evidence is available for the cellular uptake and metabolism of 
indirubins. One study in 2001 by Marko et al. determined the cellular content and
distribution of three indirubin compounds (indirubin, I3M, and indirub
 
in-5-sulfonate) 
 et al., 2001). In LXFL529L cells treated by 
ar content of indirubin and I3M (10 µM) 
y 
 activate 
mount of indirubin was decomposed/metabolized into new products, an 
t 
through HPLC with UV detection (Marko
the respective compounds for 2 hr, the cellul
did not differ significantly whereas indirubin-5-sulfonate was not detectable in the 
cells even with high concentration (50 μM). Of all the cellular content, 93 ± 6% of 
indirubin was localized in the particulate fraction whereas 43 ± 14% of I3M was 
detected in the cytosol. The highest growth inhibitory efficacy of I3M in the stud
above might be associated with its cytosolic distribution.  
Another report in 2004 by Guengerich et al. studied the metabolism of indirubins in 
vitro (Guengerich et al., 2004). Indirubin and I3M were incubated with liver 
microsomes prepared from rats that had been stimulated by corn oil or βNF (to
cytochrome P450 enzyme) with or without NADPH. HPLC profiles showed that 
limited a
NADPH-dependent process. In contrast, almost all I3M were oxidized into produc
compound, which is also NADPH-dependent.  
 
1.2 Pharmacological mechanisms of Indirubin and it derivatives 
1.2.1 Anti-inflammatory activity 
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The anti-inflammatory activity of indirubin is mainly reflected by its anti
Indirubin can inhibit viral replication or decrease viral yield. F
-virus activity. 
or example, I3M has 
een reported to inhibit Tat-induced replication of HIV-1 (primary and drug-resistance 
al blood mononuclear cells and in 
ion 
d 
dition, indirubin can 
n 
on 
ciences 1979). Indirubins have 
xhibited strong growth inhibitory effect on various human cancer cells, manifested by 
02) or 
m et al., 2005; Perabo et al., 2006; Ribas et al., 
b
strains) RNA in human cell lines, in peripher
macrophages through inhibition of CDK9 at low concentrations that did not affect cell 
proliferation (Heredia et al., 2005). I3M treatment can also significantly decrease 
cytomegalovirus yield in infected cells, attributed to its kinase inhibitory activity as 
well (Hertel et al., 2007).  
Besides, indirubin can modulate chemokine production in response to viral infection. 
In influenza virus-infected H292 human epithelial cells, indirubin inhibited the 
production of RANTES, a type of chemokine, at both the mRNA and protein level, 
although no mechanism was further investigated; in the same study, phosphorylat
of NF-kB, its regulatory molecule IkBα and the p38 MAP kinase were also observe
to be reduced after I3M treatment (Mak et al., 2004). In ad
abrogate certain cellular abnormalities induced by viral protein as in the case of huma
papillomavirus infection, where I3M rescued the abnormal centriole duplicati
induced by one of the encoded viral proteins (Duensing et al., 2004).  
 
1.2.2 Anti-cancer activity 
Indirubin was approved for clinical trials in China in the 1980’s (Institute of 
Haematology, Chinese Academy of Medicinal S
e
either cell cycle arrest (G2/M) (Hoessel et al., 1999; Yamaguchi et al., 20
cytotoxicity (mainly apoptosis) (Na
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2006; Yamaguchi et al., 2002). An in vivo study carried out in rat tumor model 
provides further evidence for the anti-tumor activity of indirubins (Kim et al., 2007)
 
1.2.2.1 Clinical trials 
Indirubin was approved for clinical trials against chronic myelocytic leukaemia (CML) 
and chronic granulocytic leukaemia (Institute of Haematology, 1979). In one of the
clinical trials, 26% of the 314 CML patients showed complete remission under 
indirubin treatment and 33%
.  
se 







ormal haematopoiesis, electroencephalogram activity and renal functions (Chang, 
 
 
Pharmacokinetics and pharmacodynamics data are not available. Minor toxicity was 
observed and mainly restricted to gastrointestinal tract, such as mild abdominal p
diarrhea, nausea and vomiting; three cases of reversible pulmonary arterial 
hypertension and cardiac insufficiency were reported (Jiang, 1986). In a similar study,
participating patients showed that indirubin had comparable efficiency as busulfan and
there was no cross-resistance between the two tested compounds (Zhang, 1985).
Before the approval for the clinical trials, long term toxicity test in dogs administering 
a high dose of synthetic indirubin (25 times of the dose for human application bas




1.2.2.2 In vitro experimental evidence 
In vitro studies of growth inhibitory effect of indirubin and its derivatives mainly 
focused on two aspects in various human cancer cell lines: effects on cell cycle 
distribution and induction of cell death. 
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1.2.2.2.1  Cell cycle 
Progression through cell cycle is tightly regulated by internal and external signals 
(Morgan, 1997).  Mitogenic factors can be the early signals that initiate entry into cell 







clin complexes can be negatively regulated by small inhibitory proteins, also 
nown as endogenous CDK inhibitors. Two families of CDK inhibitors are known: the 
), and the INK4-family (p15INK4b, 
 tumor 
, and deviations in cell cycle control are 
otentially present in all human tumors (DelSal et al., 1996). Mutations and/or 
cycle, pr ression of whic
kinases and activator/inhibitor proteins (Eisenbrand et al., 2004; van den Heuvel and 
Harlow, 1993) (Fig. 1.2).  Cyclin-dependent kinases (CDKs) play essential roles in 
cell cycle and they are activated by their binding partners, the cyclins; phosphor
status affects the activities of various CDK/cyclin complexes (Morgan, 1997)
from the G0 phase of the cell cycle, cells go through G1 phase where active DNA 
synthesis occurs to prepare for the ensuing S-phase, which is primarily associated with
cyclin D/CDK4- and cyclin D/CDK6-complexes. Cyclin D/CDK4 or 6 com
hyperphosphorylate and inactivate the retinoblastoma protein (pRb), which induces 
release of E2F transcription factors from pRb (Harbour and Dean, 2000; Tamrakar et 
al., 2000).  Consequently, E2F is activated and mediates transcription of proteins 
necessary for progression into S-phase, such as cyclin E, cyclinA, CDK1, and E2F-1 
(Mueller, 2000). At an early stage of S-phase, CDK2 associates with cyclin E and later 
with cyclin A. CDK1/cyclin B and CDK1/cyclin A govern the G2 phase during which
transition into M-phase and cell division are prepared (Sherr and Roberts, 1999). Th
CDK/cy
k
CIP/KIP-family (p21CIP/WAF1, p27KIP1, p57KIP2
p16INK4a, p18INK4c, p19INK4d/ARF). (Eisenbrand et al., 2004) 
Normal cell cycle progression is tightly controlled at distinct checkpoints. Many






Figure 1.2 Cell cycle and major regulator proteins (Eisenbrand et al., 2004)
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aberrant expression of important participants of the cell cycle have been identified, 
cluding pRb, cyclinD, CDK4, cyclinE, the INK4- and CIP/KIP-family, and many 
thers (Eisenbrand et al., 2004). Therefore inhibition of cell cycle aberration is one 
promising target for cancer therapeutics and CDK inhibiting agents represent one 
focus in this direction. 
Several studies have shown indirubin can induce cell cycle arrest at G1/G0 or G2/M in a 
variety of human cancer cells, including chronic myeloid leukemic cell K-562, 
promyelocytic leukemia cells HL-60, mammary carcinoma MCF-7 cells, breast cancer 
cell MDA-MB-231, lung cancer cell A549, and breast carcinoma HBL-100, as well as 
a few rodent tumor cell lines (Hoessel et al., 1999). Most of these cell lines displayed 
G2/M arrest when treated by dose lower than 20 µM for 24 hr, and in some the cell 
cycle arrest was followed by apoptosis whereas in the case of HBL-100, the G2/M 
arrest was reversible after removal of I3M (Damiens et al., 2001). In MCF-7 and 
MDA-MB-231 cells, reduction of the G1/G0 population was also observed (Marko et 
al., 2001; Ribas et al., 2006).  
The mechanism responsible for cell cycle arrest induced by indirubin treatment has 
remained largely unknown. Preliminary data on the expression of cell cycle regulators 
do not match very well with each other, which might be explained by different cell 
systems and experimental approaches. For example, in HBL-100 cells treated by I3M 
(15 µM for 30 hr), no alterations in most regulators of the cell cycle based on ‘Cell 
cycle 1 GEArray’ or in mRNA and protein levels of Cyclin A, cyclin B1, and CDK1 
were observed (Damiens et al., 2001), whereas in nocodazole synchronized MCF-7 
cells treated by I3M after nocodazole release, time-dependent decrease was observed 
in protein levels of CDK1, CDK1/cyclin B complex, and cyclin B in complex with 




of cyclin B increased (Marko et al., 2001).  
Another possible mechanism for cell cycle arrest induced by indirubins in tumor cell
could be due to the inhibitory effect of indirubin on the kinase activity of CDK/cycli








erz et al., 2004). 
s 
2/M-arrested MCF-7 cells, dose-depend
inhibition of CDK1 kin
the finding in HBL-100 cells (Damiens et al., 2001). Since indirubins are also effective 
inhibitors of CDK2/cyclinA and E, and of CDK4/cyclinD1, pRb phosphorylatio
treated tumor cells can be a potential target of indirubin, blocking of which can prevent 
activation of E2F as a transcription factor, ultimately leading to G1/G0 arrest 
(Eisenbrand et al., 2004). Treatment of Jurkat cells with I3M reduced phosphorylation
of pRB at Ser807/811 in a dose-dependent manner (Hoessel et al., 1999). Similar 
evidence can be found in LXFL-529L cells treated by another indirubin derivative, 
together with decreased phosphorylation of pRB at Ser780 and Ser795 (Eisenbran
al., 2004). Ser780, Ser795 and Ser807/811 are all characteristic phosphorylation sites 
targeted by CyclinD/CDK4 (M
The evidence related to cell cycle interference fortifies the anti-tumor potential of 
indirubin derivatives although the mechanisms are not well understood. Development 
and selection of novel indirubin derivatives in vivo in human tumor xenograft model
in nude mice has been reported (Eisenbrand et al., 2004). 
 
1.2.2.2.2 Cytotoxicity 
Growth inhibition effects of Indirubin and its derivatives have been observed in 
various human cancer cells, as summarized in Table 1.1. 
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 Table 1.1 Growth inhibitory effect of indirubin and its derivatives on various 
a
e 
human cancer cell lines. IC50 values are labeled if available. 
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Indirubin and its derivatives induced apoptosis has been determined based on PARP
cleavage (Nam et al., 2005), caspase activation (Kim et al., 2
 
007), Annexin V and PI 
 et al., 2007), or chrom
A staining (L 2005). But no c
e studies investigated the Bcl-2 family protein changes; down-
ti- c m as b rted  Mc urv
, 2005)  u n as  re orted (Kag lis-
Girard et al., 2007 o e ns
oxim d A  (Le  200 estin ssib
nt of m
optosis s shown using V in en
-Gi , 2007). In part  og ute
ve be to sp en ent cell de h due to the lack of 
gmenta l is se sitivity to caspase inhibitors 
, 2  e . 
 stud s that focu on the cyto t of indirubi , Xie et al  2004 
 that I3M c t gr o pop osis induce  by 
 withdra h  o 2 inase. 
e avail ble data, I3  display a ial oxicity between cancer ells 
cells, hich make it a suitabl e f r cancer therapeutics. 
itization 
has been repo ted to enha ce the Tum s actor (TN -induced a optosis 
dulation of Nuclear Factor-κB (NFκB) signaling (Sethi et al., 2006). 
y affecting the binding of N A, I3M suppressed TNF-
 et al., 2001; Kagialis-Girard atin ondensation 
hanistic stu
staining (Damiens
visualized by DN ee et al., detailed me dy was 
carried out. Som
regulation of an apoptoti ember h een repo  such as l-1 and S ivin 
(Nam et al. , although pregulatio of Bcl-2 h  also been p ia
). Cytochr me c releas  was demo trated in 5’-nitro- 
indirubinmon e treate 549 cells e et al., 5), sugg g the po le 
involveme itochondria. 
Besides ap , necrosis i  Annexin  and PI sta ing (Dami s et al., 
2001; Kagialis rard et al. icular, I3M that is hal en substit d at the 
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through mo
Without directl FκB to DN
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mediated NFκB activation in a dose- and time- dependent manner in human small cel
lung carcinoma H1299 and human embryonic kidney A293 cells. I3M can also 
suppress NFκB activation induced by carcinogens and inflammatory stimuli, such as 






g kinase, and IKKß. Other NFκB-regulated gene 
, 
enic zebra fish 
evelopment or established blood vessels. Furthermore, I3M has been observed to 
ein endothelial cell tube formation and proliferation. Despite 
2O2, TNF, okadaic acid, and PMA, which are all potent 
activators of NFκB but through different mechanisms. In-depth studies showed 
I3M blocked the phosphorylation and degradation of IκBα through the inhibition of
IκBα kinase activation and phosphorylation and nuclear translocation of p65. In 
addition, I3M represses TNF-induced NFκB-dependent reporter gene exp
following reporters have been tested: TNFR1, TNF receptor-associated death dom
TRAF2, TAK1, NFκB-inducin
products that can be inhibited by I3M include proteins involved in anti-apoptosis, 
proliferation (cyclin D1 and c-Myc), and invasion (Fig. 1.3). I3M can also suppress 
cytokine-induced cellular invasion. The understanding of I3M as a potent inhibitor of 
NFκB fortifies its promises as a therapeutic agent. 
 
1.2.2.2.4 Anti-angiogenesis 
A recent study reported that I3M had anti-angiogenic activity based on an automated
quantitative screening assay for anti-angiogenic compounds using transg
(Tran et al., 2007). I3M displayed dose-dependent anti-angiogenic activity in zebra 
fish with IC50 value of 0.31 µM, although it did not affect vasculogenic vessel 
d
inhibit human umbilical v
lacking detailed mechanistic study, the demonstrated anti-angiogenic activity of I3M 







Figure 1.3 A schematic representation of  the effect of I3M on TNF-induced NF






1.2.2.3 In vivo Animal Model  
o far, only one rat tumor model has been established to assess indirubins’ antitumor 
ctivity in accessible published literature (Kim et al., 2007). A Korean group studied 
ree novel indirubin derivatives (5-nitro-indirubinoxime, 5-fluoro-indirubinoxime, 
and 5-trimethylacetamino-indirubinoxime) both in vitro and in vivo. The experiment 
was designed as follows: RK3E-ras rat kidney epithelial cells harboring k-ras gene was 
subcutaneously inoculated on the left flank of three-week-old male Sprague-Dawley 
rats or alternatively injected into the oral mucosa. Treatment began on the 6th day after 
subcutaneous injection or 3rd day after oral injection, by direct injection of  individual 
indirubin derivative into the tumor site every other day for a total of five times. It was 
found that indirubin derivatives showed potent antiproliferative activity on oncogenic 
RK3E-ras rat kidney cells, with IC50 ranging from 1 to 8 µM and caspase-7 activation 
followed by apoptosis was observed in these cells. Direct injection of indirubin 
derivatives significantly inhibited tumor growth in Sprague-Dawley rats with RK3E-
ras-induced solid and oral tumors, which was attributed to increased apoptosis and 
decreased cell proliferation based on histological observations. 
 
1.2.3 Molecular targets of I3M 
1.2.3.1 Cyclin-dependent kinase (CDK)  
Table 
. Detailed structural study of the interaction between indirubin and CDK2 based on 
tory effect of indirubin resulted from the 
olecule into the enzyme’s ATP binding site through van 




The most well characterized property of indirubin is its function as a CDK inhibitor. 
Known kinase targets of indirubin and its derivatives have been summarized in 
1.2
crystallography revealed that the kinase inhibi
high affinity binding of the m
 16
Table 1 Kinase targets of ind.2 irubin and its derivatives. IC50 value for kinase 
 
Enzyme Indirubin I3M 
inhibition is given if available. N.A.: not available (modified from Hoessel et al., 1999





CDK1–cyclin B  10 0.4 0.18 0.055 
CDK2–cyclin A  2.2 0.75 0.44 0.035 
CDK2–cyclin E  7.5 0.55 0.250 0.15 
CDK4–cyclin D1  12 6.5 3.33 0.3 
CDK5–p35  5.5 0.8 0.1 0.065 
Erk1  > 100 > 100 > 100 38 
Erk2  43 > 100 > 100 > 100 
c-Raf  > 10 > 10 > 100 5.5 
MAPKK  > 100 > 100 > 100 3 
c-Jun N-terminal 
Kinase > 100 21 N.A. 5.2 
Protein kinase C α > 100 > 100 27 > 100 
Protein kinase C ß 1 > 100 > 100 4 > 100 
Protein kinase C ß 2 > 100 > 100 20 6.5 
Protein kinase C γ > 100 > 100 8.4 > 100 
Protein kinase C δ > 100 > 100 > 100 > 100 
> 100 > 100 20 > 100 Protein kinase C ε 
Protein kinase C η > 100 52 > 100 > 100 
Protein kinase C ζ > 100 > 100 > 100 > 100 
cAMP-dependent 
protein kinase  > 1,000 600 6.3 > 1,000 
cGMP-dependent 
protein kinase  > 1,000 380 9 480 
Casein kinase 1 8.5 28 9 10 
Casein kinase 2 > 100 > 100 12 1.5 
Insulin- receptor 
tyrosine kinase > 1,000 550 11 320 
c-Src tyrosine kinase 18 10 N.A. 3.8 
c-Abl tyrosine kinase  > 1,000 > 1,000 N.A. > 1,000 
GSK 3 0.60 0.05 0.022 0.28 
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inhibition of GSK-3ß by indirubin is achieved through its binding to the ATP pocke
(Leclerc et al., 2001), suggesting a common interaction between indirubin and kinases. 
Detailed analyses of the in
t 
teraction and possible molecular modifications for improved 
potency have been reviewed by Eisenbra  2004. The potent kin y 
r some reported biological effects of indirubins. For 
ibition of CDK9 – the catalytic subunit of Positive transcri
r b (P-TEFb y I3M con s to the su ed HIV-1 replication 
Fb (Hered t al., 2005). Indirubin comp  inhibit not  
kinases but also phosphorylase. It is reported that indirubin-5-sulphonate inhibits 
en phosphorylase wit s extensiv ction com  to that o 2 
opoulou et al, 2004). These evidence gest that indirubin applications have a 
e of implications  its enzym itory pro
portant 
irubin deri es have been shown 
onstituti t3 signalling in human breast cancer cells (MDA-MB-
study revealed that the 
inase by indirubin derivatives led to decreased tyrosyl 
f Stat3 a by suppressed Stat3 DNA binding-activity, which 
d the tar  of Stat3, such as the anti-apoptotic protein Mcl-1 
am et al., 2005) 
nd et al in ase inhibitor
activities are responsible fo
example, the inh ption 
elongation facto ) – b tribute ppress
mediated by P-TE ia e ounds  only
glycog h les e intera paring f CDK
(Kosm s sug
wide rang  due to e inhib perty. 
 
1.2.3.2 Src kinase and Stat3 signalling pathway  
Stat3 signalling pathway has an im role in oncogenesis and therefore Stat3 
protein is a promising anticancer target. Three ind vativ
to potently block c ve Sta
468/-435) and prostate cancer cells (DU145). Mechanistic 
inhibition of Src k
phosphorylation o nd there
ultimately affecte get genes
and Survivin. (N
 
1.2.3.3 Aryl hydrocarbon receptor (AhR) 
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Aryl hydrocarbon receptor (AhR), a member of the bHLH/PAS family of 
transcriptional factors, mediates the responses of some xenobiotics including indole-
containing compounds (Denison and Nagy, 2003). Upon ligand binding, AhR 
translocates from the cytoplasm to the nucleus and then binds to xenobiotic-responsive 
element, which stimulates the transcription of various genes including cytochrom
P450 Cyp1A1 (Knockaert et al., 2004). The possibility of indirubins to be the 
physiological ligands of AhR was initially tested in yeast, and then proved in 
mammalian systems using in vitro and in vivo assays (Guengerich et al., 2004). 
Several studies provide evidences for a link between AhR activation and cell cycle
control; using AhR-/- and +/+ cells and indirubin derivatives incapable of kinase 
inhibition, Knockaert et al (2004) suggested that AhR activation, rather than kinase 
inhibition, was responsible for the cytostatic effects of some indiru
e 
 
bins. In contrast, the 




e (Leclerc et al., 2001). In addition, I3M can inhibit 
SK-3ß activation in MPTP-induced Parkinsonism models and prevent dopaminergic 
 fro cluding apoptosis, depletion of striatal 




1.2.3.4 Glycogen synthase kinase-3 (GSK3) 
Glycogen synthase kinase-3 (GSK3) plays critical roles in neuronal apoptosis and 
pathogenesis, especially neurodegenerative diseases. For example, GSK-3ß togeth
with CDK5 is responsible for most abnormal Tau protein hyperphosphory
Alzheimer’s disease. Indirubins can bind to GSK-3ß’s ATP pocket and inhibit its 
kinase activity, which explains how I3M prevented tau phosphorylation in vitro and in
vivo at sites of Alzheimer’s diseas
G
neurons m MPTP-induced neurotoxicity, in
 19
potential application of indirubin derivatives in the prevention of neurodeg
diseases. 
 
1.2.3.5 c-Jun NH2-terminal kinase (JNK) 
Kinase assay showed that I3M could inhibit all three isoforms of JNK in vitro. In 
cerebellar granule neurons, JNK activation induced by potassium withdrawal c
blocked by I3M in a dose-dependent manner; consequent inhibition of c-Jun 
phosphorylation correlated with reduced apoptosis. It is also postulated that I3M
inhibits JNK through a mechanism different from its kinase inhibition, since other 
inhibitors of CDKs and GSK-3ß were ineffective in suppressing c-Jun phosphoryl
(Xie et al., 2004). The evidence suggests the kinase inhibitory property of indirubin 







ibroblast growth factor receptor 1 (FGFR1) 
 cells stimulated by FGF-1, I3M inhibits autophosphorylation of FGFR1 and DNA 




synthesis, but it does not affect FGF-1 binding to
ligand-receptor complex. Although the nature of the inhibition is still elusive, it is 
suggested that at low I3M concentration (5 µM) cell cycle is blocked by inhibiting the
tyrosine kinase activity of FGFR1 whereas at higher concentration cell cycle 
interference by I3M is FGFR-independent. Furthermore, I3M inhibits the prolifera
of FGFR-dependent cancer cells through inhibiting the tyrosine kinase activity of 
FGFR1 (Zhen et al., 2007).  
An interesting finding in Zhen’s study (2007) is that I3M, instead of inhibition, 
activates long-term p38 mitogen-activated protein kinase (p38 MAPK), an activity 
unrelated to the FGFR activity, which in turn stimulates extracellular signal-regulated 
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kinase 1/2 (ERK1/2). Evidence in this study also shows that I3M increased 
phosphrylated JNK, contrary to Xie’s study in 2004; the opposite results from two 
tudies might due to different cells utilized: the former one used mouse embryonic 
e used primary cerebellar neuronal cells 
imental or functionally useless (Twomey and 
cCarthy, 2005). Apoptosis was originally described based on morphological studies 




97; Ranger et al., 2001; Yeh et al., 1999). Disturbance of 
ncer 
s
fibroblast cell line (NIH/3T3) and the latter on
from rats, suggesting cell type specific behavior of indirubin derivatives. 
 
1.3 Apoptosis 
1.3.1 General introduction 
Apoptosis, also termed as programmed cell death, is a conserved death pathway in 
mammals as well as lower organisms such as Caenorhabditis elegans and Drosophila 
melanogaster, required by multicellular organisms for regulating cell numbers or 
eliminating cells that are potentially detr
M
of developing vertebrate embryos, where isolated dying c
shrinkage, chromosomal condensation and cell fragmentation (Kerr et al., 1972). The 
elimination of cells by apoptosis is a fundamental event for successful embryonic 
development in terms of organogenesis and formation of complex multicellular tis
apoptosis also functions in adult organisms to maintain tissue homeostasis (Danial and 
Korsmeyer, 2004), the critical role of which has been determined in genetic st
through the generation and functional characterization of overexpressing and/or 
deleting genes of the central apoptotic pathway in murine models (Colussi and Kum
1999; Hawkins and Vaux, 19
the cellular homeostasis can be pathogenic: insufficient apoptosis can result in ca
or autoimmune diseases whereas overactive apoptotic events are observed in 
degenerative diseases or immunodeficiencies.  
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 1.3.2 Apoptotic pathways 
The apoptotic machinery is widely conserved across species (Fig. 1.4). Studies of 
developmental cell death in C. elegans provided the first evidence for genes involved 
in apoptosis (Ellis and Horvitz, 1986), and led to the identification of several critical 
enes, such as ced-3. ICE (interleukin-1-ß-converting enzyme), initially identified as a 
rotease responsible for processing pro-IL-1ß, was shown to be 









functional homologue of ced-
that cystine proteases are essential components of apoptosis; homologues of the oth
apoptotic genes involved in cell death of C. elegans have also been identified and 
shown to be evolutionarily conserved (Chinnaiyan, 1999; Putcha and Johnson, 200
Riedl and Shi, 2004). The mammalian homologues of ced-3 genes are defined as 
caspases (cystine-aspartate protease); 11 out of 14 identified so far are of human origin
(Shi et al., 2002).  
The caspases that are involved in apoptosis are functionally subdivided into two 
categories: the initiator caspases and the effector caspases. Long pro-domains pres
in initiator caspases, death effector domain (DED) in pro-caspase 8 and 10 and caspase 
recruitment domain (CARD) in pro-caspase 2 and 9, are responsible for the 
oligomerization and autocatalytic activation of initiator caspases, which leads to the 
activation of effector caspases (pro-caspase 3, 6 and 7) by cleaving their short pro
domain (Twomey and McCarthy, 2005). Downstream of effector caspase activation, 
cellular substrates in the cytoplasm or nucleus are cleaved, resulting the morphologic 
features of apoptosis (Degterev et al., 2003). There are primarily two apoptotic 
pathways in mammalian cells: extrinsic pathway initiating at the plasma mem
 22
upon ligation of death receptors and intrinsic pathway at mitochondria (Putcha et al., 














Figure 1.5  Apoptotic pathways in mammalian system (Twomey and McCarthy, 
2005). 
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1.3.2.1 Receptor-mediated apoptosis 
ctivation of the death receptors results in caspase-8 activation and direct cleavage of 
ownstream effector caspases such as caspase-3 (Vogler et al., 2007). Death receptors, 
embers of the tumor necrosis factor (TNF) receptor gene superfamily, are 
istinguished from the other members of the superfamily by the presence of a 
cytoplasmic ‘death domain’, which is critical for the transmission of death signals 
from cell surface. There are several well characterized death receptors including Fas 
(Apo-1/ CD95), TNF receptor 1 (TNFR1), and TNF-related apoptosis-inducing ligand-
receptor 1 or 2 (TRAIL-R1/DR4 or TRAIL-R2/DR5) (Walczak and Krammer, 2000); 
their corresponding ligands are Fas ligand (FasL), TNFα, and TRAIL.  
Signalling proteins interacting with death receptors possess a diverse set of modular 
protein motifs enabling homotypic interaction, including death effector domain (DED) 
and death domains (DD) (Itoh and Nagata, 1993) (Fig. 1.6). Fas, preassembled as a 
trimer, recruits adaptor FADD through DD domain, which in turn binds procaspase-8 
via DED domain (Kischkel et al., 1995); together a signaling complex is formed on the 
cytoplasmic side of Fas, known as death-inducing signaling complex (DISC) (Muzio 
et al., 1996). High proximal concentration of caspase-8 is believed to induce 
. 
ctivation leads to similar DISC complex formation and downstream events as 
the Fas pathway (Ashkenazi and Dixit, 1998). In the case of TNFR1, distinct complex 
formation occurs in a temporal pattern: within minutes of activation a TNFR1 complex 
(complex I) including TRADD, TRAF2, cIAP1, and RIP1 assembles at the plasma 
membrane to attract IKK and therefore activate the survival pathway of NF-kB; 
subsequent dissociation of complex I from TNFR1 can recruit FADD and pro-





autoproteolysis and subsequent proteolysis of caspase-3 and -7 (Scaffidi et al., 1998)
DR4/5 a
 25
insufficient and inadequate cFLIP, an inhibitor of caspase-8, is expressed, complex II 




Figure 1.6 Extrinsic death receptor pathways (Danial and Korsmeyer, 2004) 
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1.3.2.2 Mitochondrial-mediated apoptosis 
The intrinsic pathway of apoptosis is closely related to mitochondrial permeabilization 
f the outer membrane, induced by various cytotoxic stimuli and proapoptotic 
ed by proteins from the Bcl-2 family, 
various functional protein components of the outer membrane, and mitochondrial 
lipids (Green and Kroemer, 2004). Upon permeabilization of the outer membrane, a 
group of proteins inside the intermembrane space is release to the cytosol, including 
cytochrome c, Smac/DIABLO, Omi/HtrA2, AIF and endonuclease G (Saelens et al., 
2004). 
The release of cytochrome c induces the formation of the apoptosome complex 
containing cytochrome c, Apaf-1, and caspase-9. Cytochrome c binds to the C-
terminal of Apaf-1, which facilitates the association of dATP with Apaf-1 and 
exposure of the N-terminal CARD domain. Initiator caspase-9 is then recruited and 
activated through the CARD-CARD domain interaction; subsequently, executioner 
caspase-3 is activated by caspase-9 and cleaves downstream substrates. In addition, 
membrane permeabilization can cause secondary events such as the drop of 
mitochondrial membrane potential (MMP) and deterioration of the normal function of 
 
oxygen species generation (Ricci et al., 2004). There is evidence suggesting a 
cytochrome c-/apoptosome-independent but Apaf1-dependent caspase activation 
(Fulda and Debatin, 2006). 
Other proteins released from the intermembrane space of mitochondria, such as 
Smac/DIABLO and Omi/HtrA2, promote caspase activation through antagonizing 
endogenous inhibitors of caspases – the inhibitor of apoptosis proteins (IAPs) (Fulda 
and Debatin, 2006). Omi/HtrA2 can also contribute to cell death by degrading XIAP, 
o
signaling molecules. The process is regulat
complexes I and II, ultimately resulting in mitochondrial dysfunction and reactive
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cIAP1, c P2 and Apollon as a protease (SuzuIA ki et al., 2004). Besides, AIF and 
lens et 
 
xecutioner caspase-3, whereas in type II cells, activated caspase-8 induced by 
els. In 
 
regulators of apoptosis through controlling the 
rial 
 
endonuclease G translocate to nucleus upon release form mitochondria and contribute 
to chromosomal condensation and DNA fragmentation (Cande et al., 2004; Sae
al., 2004). 
 
1.3.2.3 Type I and type II cells 
For CD95 and TRAIL signaling pathway, two cell prototypes are distinguished. 
Type I cells activated sufficient caspase-8 through DISC complex for direct activation
of the e
death receptor is insufficient for full activation of effectors caspases and the 
mitochondrial participation is then required (Fulda et al., 2002). 
Cross talk between the extrinsic and intrinsic pathway can occur at different lev
response to signals from death receptors, activated caspase-8 may cleave Bid, a BH3
domain only member of the Bcl-2 family, which subsequently translocates to 
mitochondria, and assists the release of cytochrome c, initiating the mitochondrial 
amplification loop (Cory and Adams, 2002). Furthermore, the activation of 
mitochondrial pathway, resulting caspase-6 activation, may feed back to the receptor 
pathway through cleavage of caspase-8 (Cowling and Downward, 2002). 
 
1.3.3 Bcl-2 family 
Bcl-2 family proteins act as 
mitochondrial membrane permeability by pore-formation in the outer mitochond
membrane (Tsujimoto, 2003). According to the structural and functional 
characteristics, they are categorized as anti-apoptotic members (Bcl-2, Bcl-XL, Mcl-1,
 28
A1, and Bcl-w), multi-domain pro-apoptotic members (Bax, Bak) and BH3-only 
apoptotic members (Bid, Bad, PUMA and NOXA)(Cory and Adams, 2002).  
The anti-apoptotic members display conservation in 4 conserved regions termed Bcl-2 
homology (
pro-
BH) 1-4 domains; structural study from Bcl- XL reveals that BH1, BH2 and 
H3 domains form a hydrophobic pocket which is capable to accommodate a BH3 









ost BH3-only proteins function as death signal sensors which selectively respond to 
s uli (Danial and Korsmeyer, 2004). Bid can be cleaved by 
on to the 
regulated by p53 in response to DNA damage (Yu et al., 2001). Activation of BH3-
B
domain of a pro-apoptotic Bcl-2 me
pro-apoptotic members (Bax, Bak) shared BH1-3 domains, and an activation eve
required to expose the hydrophobic portion of their BH3 domain for their interaction 
with Bcl-2 and Bcl-XL (Danial and Korsmeyer, 2004). Cells deficient for Bax and Bak
proved resistant to most stimuli of the intrinsic pathway (Wei et al., 2001). In
unstimulated cells, multi-domain Bax and Bak remain as monom
exists in the cytosol or is loosely attached to the mitochondrial membrane; upon 
receipt of a death signal, Bax undergoes conformational change and its N-terminal 
portion becomes exposed (transformed Bax) (Desagher et al., 1999). Bax and 
insert into the mitochondrial outer membrane as homo-multimers and ultimately lea
to membrane permeabilization and release of proteins from intermembrane s
(Danial and Korsmeyer, 2004). But the exact interaction of Bax and Bak and the 
precise mechanism by which proteins are released are still under investiga
M
variou  apoptotic stim
caspase-8 and followed by N-myristoylation, which facilitates its translocati
mitochondria. The intact BH3 domain of Bid can then trigger the oligomerization of 
Bax or Bak (Desagher et al., 1999). Bad is activated or deactivated by its 
phosphorylation status (Zha et al., 1996); PUMA and NOXA are transcriptionally 
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only proteins can directly or indirectly activate Bax and Bak whereas antiapoptotic 
proteins, such as Bcl-2 or Bcl-XL, can bind and sequester BH3-only proteins to prevent 
f 




Bax and Bak activation and hence the amplification of the mitochondrial pathway. 
 
1.3.4 Other regulatory mechanisms 
Other than Bcl-2 family members, IAPs (XIAP, cIAP1, cIAP2) also contribute to the 
regulation of apoptosis by modulating caspase activation. IAPs can inhibit caspase 
enzyme activity by direct interaction with the enzymatic domain or indirect blocking 
of substrate access (Riedl et al., 2001; Srinivasula et al., 2001). Therefore the 
degradation if IAPs can augment the activation of caspase cascade. 
 
1.3.5 Apoptosis and cancer 
Disruption of the apoptotic pathways is one of the strategies cancer cells utilize to 
resist cell death.  
In response to death receptor ligand binding, the signaling process to induce apoptosis 
can be disturbed by impaired surface expression of CD95 or TRAIL receptors at 
different levels. One possible mechanism is through down-regulation or absence o
death receptors on cell surface as in the case of drug-resistant leukemia or 
neuroblastoma cells where CD95 expression is strongly down-regulated (Friesen et al., 
1997). Mutated CD95 genes have also been identified in various tumors (Debati
2003). Loss of functional TRAIL receptors (DR4 and DR5) expression (LeBlanc and 
Ashkenazi, 2003), deficient transport of DR4 and DR5 from intracellular protein 
synthesis stores (Jin et al., 2004), or the presence of decoy receptor for TR
et al., 1999), all can confer TRAIL resistance to cancer cells. Epigenetic alteration 
death receptor genes, such as CpG-island hypermethylation and changes in chromati
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structure (Marks et al., 2001), can also contribute to the resistance to apoptosis in 
cancer cells. Moreover, interference to DISC complex formation has also been 
observed. Two variants of FLIP, a long form (FLIPL) and a short form (FLIPS), present 
 human cells have sequence homology with caspase-8 and caspase-10 but without 
ti ); therefore binding of FLIP to DISC complex 
r cells. 
verexpression of the anti-apoptotic Bcl-2 members is a dominant approach utilized 
a (Tsujimoto et al., 1984); genetic mutations that 
as 





cataly c activity (Krueger et al., 2001
instead of caspase-8/-10 forestalls caspase activation, which explains the high 
expression level of FLIP in many tumor cells resistant to CD95-/TRAIL- or drug-
induced apoptosis (Longley et al., 2006). PEA-15 is another protein that can interfere 
FADD and capase-8/-10 interaction (Hao et al., 2001). 
Disruptions to the intrinsic pathways are also very common in cance
O
by human follicular lymphom
inactivate the Bax gene have been observed in hematological malignancies as well 
some solid tumors
mutations, deregulation of Bcl-2 family members can be due to transcriptional or post-
transcriptional modification, such as regulation by NFκB (Cory and Adams, 2002
Decrease or absence of Apaf-1 activity has also been observed in a variety of tumors
(Fulda and Debatin, 2006).  
Furthermore, mutations in some important tumor suppressor genes are crucial for 
cancer development since they can impinge on the apoptotic pathways (Brown and 
Attardi, 2005). For example, p53 mutation is most frequently detected in human 
cancers. Both death receptors (DR4 and DR5) (Liu et al., 2004; Pistritto et al., 200
and pro-apoptotic BH-3 only proteins (PUMA, NOXA and Bid) (Oda et al., 2000; Sax 
et al., 2002; Yu et al., 2001) have been known to be transcriptionally regulated by 
activated p53. In addition, recent evidence suggests that p53 can directly promote 
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mitochondrial destabilization through binding with Bcl-2 and Bcl-XL, independent
its transcriptional activity (Mihara et al., 2003). 
 
1.3.6 TRAIL signaling pathway as potential therapeutic target  
TRAIL is a promising candidate for clinical applications because it is relatively safe 
comparing to CD95L or TNFα (Walczak and Krammer, 2000), which is furthe
supported by toxicity tests in non-human primates (Ashkenazi et al., 1999). TRAIL
has also been proved for its efficacy to induce apoptosis in a wide spectrum of cancer 








roteins including FLIP, Bcl-2 or Bcl-XL (Olsson et al., 
y, 
(Fulda and Debatin, 2006). 
Despite the non-toxicity and prominent efficacy of TRAIL, TRAIL resistance occurs 
in certain tumors due to dominant anti-apoptotic signals; yet numerous studies h
provided strong evidence for the sensitization of TRAIL-induced apoptosis by 
cytotoxic drugs or γ-irradiation. Various mechanisms have been identified in th
context of a specific therapeutic combination and cell type, including transcriptional 
upregulation of the functional DR4 and DR5 (Meng and El-Deiry, 2001; Takimoto a
El-Deiry, 2000), enhanced TRAIL receptor assembly (Lacour et al., 2004), down-
regulation of anti-apoptotic p
2001), and up-regulation of pro-apoptotic proteins such as FADD or caspases 
(Micheau et al., 1999). Since many chemotherapeutics target on the intrinsic pathwa
co-treatment with TRAIL can elicit both the mitochondrial and death receptor 
pathway, resulting in an augmented apoptotic response (Fulda and Debatin, 2006). 




1.4 Objectives of the study 
The main objective of this project is to study the molecular mechanisms involved in 





specific aims of the study include the following: 
(1) To examine I3M-induced apoptosis in various human cancer cells 
(2) To determine the apoptotic pathway underlying I3M-induced apoptosis  
(3) To evaluate the critical role of Bcl-2 family members in I3M-induced apopto











Chapter 2 Materials and Methods 
2.1 Reagents, chemicals and plasmids 
Indirubin-3’-monoxime (I3M), 4’,6-diamidino-2-phenylindole (DAPI), thiazolyl blue 
tetrazolium bromide (MTT), cycloheximide (CHX) and TNFα were purchased from 
Sigma (St Louis, MO, USA). Propidium iodide (PI) was purchased from Molecular 
Probe (Eugene, OR, USA). Protease inhibitor cocktail was obtained from Roche 
(Mannheim, Germany). Pan caspase inhibitor z-VAD-FMK, caspase-8 inhibitor ac-
IETD-CHO and caspase-9 inhibitor ac-LETD-CHO were purchased from Biomol 
(Plymouth meeting, PA, USA); caspase-3 inhibitor z-DEVD-FMK was from 
Calbiochem (San Diego, CA, USA). Other mmon chemicals were from Sigma. Anti-
PARP, anti-caspase-8, anti-bid, anti-caspase-9 (human specific), anti-caspase-3, and 
anti- COX IV antibodies were pur naling (Beverly, MA, USA), 
anti-Bax (N-20) polyclonal (C-19) antibody and goat 
anti-rabbit IgG HRP from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-
ytochrome c monoclonal antibody from Pharmingen (San Diego, CA, USA), anti-α-
tubulin monoclonal antibody from Sigma, and ImmunoPure® peroxidase conjugated 
goat anti-mouse IgG (H+L) from Pierce (Rockford, IL, USA).  
 
2.2 Cell culture 
Human cervical cancer cell line HeLa, human hepatoma cell line HepG2, human 
colorectal cancer cell line HCT116, and human colorectal cancer cells HT29 were 
obtained from American Type Culture Collection (Manassas, VA) and human 
nasopharyngeal cancer cells CNE1 were obtained from Sun Yet-sat University 
(Guangzhou, China); they were maintained in Dulbecco’s modified Eagle’s medium 
co
chased from Cell sig
, anti-p53 (FL-393), and anti-p21 
c
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(DMEM) (Sigma) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, 
UT, USA) and antibiotics (Invitrogen, Carlsbad, CA, USA). Treatment details with 







estern blot analysis was performed as previously described (Zhou et al., 2006). 





I3M were illustrated in figure legends. All th
min before treatment. 
 
2.3 Growth inhibition test: MTT 
MTT assay has been frequently used as an indication of growth inhibition (Hanse
al., 1989). Human cancer cells were seeded into 96-well plate 18 hr prior to various 
treatments; each treatment group was seeded in triplicate; a group of empty wells w
used as blank control. At the end of the treatment, medium in each well was re
and 25 µl of MTT (5mg/ml in sterilized PBS) was added. After 1 hr incubation at 37ºC 
with protection from light, 100 µl lysis buffer (50% DMF and15% SDS in dd-H2O, pH
4.6 ~ 4.7) was added into each well; the plates were shaked on an orbital shaker till a
the crystal formed dissolved completely. The absorbance reading was recorded by a 
microplate reader Tecan® SPECTRAFLUOR PLUS (MTX Lab Systems, Inc.,Vienna)
the wavelength of 590 nm. 
 
2.4 Western Blot 
W
Who cell lysate wa
0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol (DT
0.5 mM phenylmethylsulfonyl fluoride (PMSF), 20 mM ß-glycerol phosphate, 1 mM
sodium vanadate and 1x protease inhibitor cocktail) and insoluble fractions wer
discarded after centrifugation at 15,000 g for 18 min. Equal amount of proteins w
fractionated on SDS-PAGE gel in the Mini-PROTEAN II system (Bio-RAD) and 
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blotted onto PVDF membrane (Millipore). After blocking with 5% nonfat milk in 
TBST (10 mM Tris-HCl, 100 mM NaCl and 0.1% Tween-20), the membrane was 
probed with various primary antibodies followed by corresponding secondary 
antibodies, and then developed with enhanced chemiluminescence (Pierce) using a 
odak Image Station 440CF (Kodak). α-Tubulin was used as loading control.  
fter sucking out media gently, adhesion cells were washed once with 1x PBS (NaCl 
mM 2HPO4 10 mM, and KH2PO4 2 mM in ddH2O, pH 7.4), then 
ng 
for 





2.5 Detection of apoptosis 
Human cancer cells were treated by I3M and then the apoptosis were detected using 
the following methods: (i) Morphological changes were observed under light 
microscope; and chromosomal condensation was detected by DAPI staining as 
previously described (Zhou et al., 2006). (ii) Percentage of the sub-G1 cells was 
measured by FACS Calibur (BD Biosciences, Heidelberg, Germany) using propidium 
iodide (PI) staining (Shen et al., 2000). (iii) PARP cleavage was detected in whole-cell 
lysate by western blotting. 
 
2.5.1 DAPI staining 
A
137 , KCl 2.7 mM, Na
fixed with 70% ethanol (stored at -20ºC) for 2 min at room temperature. After bei
washed with 1x PBS gently, cells were stained by DAPI solution (3 µg/ml in PBS) 
5 min at room temperature. DAPI stock solution (6 mg/ml in DMSO) was kept at -20º
C or -80ºC for long-term storage. Stained cells were washed again with 1x PBS gently 
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2.5.2 PI staining followed by flow cytometry 
106 to 107 Cells were collected and suspended in 1x PBS in a centrifuge tube. After
centrifugation at 800 g for 5 min, cells were washed with 1x PBS and transferr
eppendorf tube. Cells were resuspended in 50 µl of PBS and 450 µl of 70% ethanol 
(stored at -20ºC). Cells were fixed in ethanol for at least 2 hr. The ethanol-susp
 
ed to an 
ended 
ells were spun down by 800 g for 5 min and ethanol was decanted thoroughly. Cells 
 w and suspended in 500 µl PI/Triton X-100 staining 
 for 
A) following manufacturer’s instruction. 100 µl of Apo-
ne® Caspase-3/7 reagent was added to each well of a 96-well plate containing 100 µl 
ls in culture. The contents of wells were mixed gently using a 
 
s of death receptors 
ot more than one million HeLa cells, untreated or treated with I3M (20 μM×24 hr), 
ere stained with Phycoerythrin (PE)-labled DR4 or DR5 (eBioscience, San Diego, 
c
were ashed once with 1x PBS 
solution with RNase A (PI 20 µg/ml, Triton X-100 0.1%, and RNase A 0.2 mg/ml in 
PBS) for 15 min at 37ºC or 30 min at room temperature. Cells were then ready
analysis by FACS Calibur. 
 
2.6 Measurement of caspase activity 
Caspase-3/7 activity was examined by Apo-One® Homogeneous Caspase-3/7 Assay 
(Promega, Madison, WI, US
O
of blank, control or cel
plate shaker at 300-500 rpm. The plate was then incubated at room temperature for1.5 
hr (the incubation time can be from 30 min to 18 hr; the optimal incubation period is 
determined empirically). After incubation, the fluorescence intensity was measured at
an excitation wavelength range of 485±20 nm and an emission wavelength range of 
530±25 nm using Tecan SpectraFluor Plus (Tecan, Durham, NC, USA). 
 




CA, USA) at room temperature for 30 min at dark. To control for nonspecific binding, 
e 
hieved at the point of transfection. Negative control siRNA, 
nd validated siRNA duplex targeting human Bid and Lamin A/C were purchased 
 D iRNA was carried out by using 
TM
ot. 
CCATAGAGGATGGTCTTAC TTCAAGAGA GTAAGACCATCCTCTATGG 
TTTTTGGAAA 3’; reverse strand 5’ AGCTTTTCCAAAAA 
CGATAGAGGATGGTCTTAC TCTCTTGAA TAACCATTCGTGGGTGGTC 
GGG 3’, which carries a neomycin selection marker (a gift from Dr. Song ZW, BTI, 
A*Star). Corresponding control HeLa cells expressing empty pSuper vector with 
PE-conjugated mouse IgG1, K isotype control were used as isotype-matched 
nonbinding antibodies. 20 μl of each of the specific antibodies or the isotype antibody 
together with 30 μl staining buffer was used for each sample. Cells were washed onc
with staining buffer before analysis by FACSCalibur using Cellquest software (BD). 
 
2.8 Transfection 
2.8.1 Transient transfection of siRNA 
HeLa cells were seeded 12-24 hr before the transfection in antibiotics-free medium 
and 30% confluency was ac
a
from harmacon. The cellular delivery of s
Lipofectamine  2000 (Invitrogen) according to the manufacturer’s instructions, 
optimized with various doses and post-transfection time, and evaluated by western bl
Cells were treated with I3M 72 hr after siRNA transfection, and apoptotic cell death 
was evaluated by PI staining followed by flow cytometry analysis.  
 
2.8.2 Stable transfection of vector expressing Bid siRNA 
HeLa cells with stable knockdown of Bid, was generated using pSuper vector 
containing the following sequence: forward strand 5’ GATCCCC 
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neomycin selection marker were also generated. After transient transfection of the 
above pSuper vectors, cells that survived two weeks of selection were used to 
single cell clones by limiting dilution. G418 Sulfate (Promega) 500 µg/ml was applied 
in the complete DMEM medium during selection and after selection, but not during 
any treatment. 
generate 
 cl-2 or CrmA transfected cells using flow cytometry 





ol samples with or 
ithout GFP expression. After 48 hr of transfection, the cells were treated with 20 µM 





2.8.3 Detection of B
HeLa ells were seeded 12 hr before the 
90% confluency was achieved at the point of transfection. Cells were transfected wit
pcDNA3.1 empty vector, Bcl-2 expression vector or CrmA expression vector (a kind 
gift from Dr. ZG Liu, NCI, USA) using LipofectamineTM 2000 (Invitrogen) accordi
to the manufacturer’s instructions; pmaxGFP vector (Amaxa Inc., Gaithersb
USA) was co-transfected as a transfection marker and only successful transfected 
were analyzed as described before (Won et al., 2005). Briefly speaking, only cells 
expressing GFP, as detected by FACSCalibur, were analyzed for their DNA content 
and presented in the data. The voltage used was determined by contr
w
I3M for 24 hr. Cell death was determined by percentage of s
morphological changes examined under inverted fluorescent microscope (Niko
Tokyo, Japan). 
 
2.9 Detection of Bax conformational change 
2.9.1 Immunofluorescence 
HeLa cells were seeded in 8-well chamber slides (Nalge Nunc, Rochester, NY, USA)
24 hr before treatment. After treatment cells were fixed in 3% paraformaldehyde f
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30 min at room temperature and permeablized for 2 min with 0.2% CHAPS in PBS
After blocking with 1x PBS containing 0.2% Tween-20, 5% FBS and 3% BSA for 1 
hr, cells were incubated with anti-Bax 6A7 antibody overnight at 4ºC. After washing 




ody for another 1 hr at room temperature. Coverslips were mounted 
nto slides using ProLong anti-fade mounting reagent (Molecular Probes). Cells were 
 60x oil 
, 25 µl 
-
re washed carefully in CHAPS lysis buffer for 3 times and then boiled 
 loading buffer containing 5% ß-mercaptoethanol. Conformational changed Bax in 
lot using anti-Bax polyclonal 
o




Immunoprecipitation was carried out as previously described (Zhou et al., 2006) with 
minor changes. Briefly, cells were lysed in CHAPS lysis buffer (10 mM Hepes, pH 
7.4, 150 mM NaCl, 1% CHAPS) containing protease inhibitors (Yamaguchi et al., 
2002). The cell lysates were normalized for protein content and pre-cleared by 
incubating 500 µg of total protein with 50 µl of protein G-agrose for 60 min on ice. 
After spinning at 10,000g for 10 min, pre-cleared lysate (supernatant) were transferred 
to a new eppendorf tube and incubated with 2 µg of anti-Bax 6A7 monoclonal 
antibody (Sigma) in 500 µl of CHAPS lysis buffer overnight at 4ºC. Afterwards
of protein G-agrose were added and incubated for additional 3 hr at 4ºC. Protein G
agrose beads we
in





2.10 Subcellular fractionation 
Whole-cell lysate was prepared using M2 buffer as described above. Cytosolic and 
nuclear fractions were obtained according to a protocol previously described with 
minor modifications (Zhou et al., 2006). In brief, sample cells were harvested and 
centrifuged at 1,500 rpm for 5 min. The pellet was washed with ice-cold PBS and 
resuspended in isotonic homogenization buffer (10 mM Tris-HCl, 250 mM sucrose, 10
mM KCl, 1.5 mM MgCl2, 1 mM PMSF, 1 mM DTT, and 1x protease inhibitor 
cockta
 
il, pH 6.7); cells were incubated on ice for 10 min and homogenized by passing 
rough a syringe with gauge #27 needle for 15 min at 4ºC. The lysate was then 






.12 Statistical analysis 
th
subjec  to a series of centrifug
20 min to fractionate intact cells, nuclei and mitochondria, respectively. The 
supernatant generated after a final centrifugation of 60,000 g for 30 min was collecte
as the cytosolic fraction. The mitochondria pellet was dissolved in M2 buffer and th
soluble lysate was taken as the mitochondrial fraction. 
 
2.11 Long-term clonogenic assay 
5000 cells are seeded into each well of a 6-well plate 24 hr before treatmen
designated treatment, treatment medium is changed to complete medium and cells are 
allowed to grow for about 1 week or longer depending on cellular growth rate. T
cells were fixed by 3% paraformaldehyde for 30 min at room temperature and stained 
by 1% crystal violet for 1 hr at room temperature. After 3 times wash with 1x PBS, th




All numerical data were presented as mean ± S.D. of at least three independent 
d 
experiments. Statistical significance was assessed by Student’s t-tests (two-tailed 










Chapter 3 Results  
3.1 I3M induces apoptosis in a time- and dose-dependent manner in human 
cancer cells 
With I3M treatment, we observed the characteristics of apoptosis – membrane 
blebbing, chromosomal condensation and DNA fragmentation in HeLa, HepG2 and 
HCT116 (Fig. 3.1). Growth inhibitory effect of I3M on the cancer cells was measured 
using MTT assay (Fig. 3.2). I3M-induced apoptosis was quantified using sub-G1 
analysis; we observed a time- and dose-dependent manner in the three cancer cells 
(Fig. 3.3A & B). Among them, HeLa cells are most susceptible to I3M. In addition, 
PARP cleavage, another hallmark of apoptosis, was also detected in HeLa cells in a 
similar time- and dose-dependent pattern (Fig. 3.3C). Similar results were observed in 
HepG2 and HCT116 cells. 
 
3.2 I3M leads to caspase activation 
To understand the apoptotic machinery involved in I3M-induce apoptosis, we 
examined the caspase activation. Evident caspase-8 cleavage commenced at 12 hr and 
almost all were cleaved at 24 hr (Fig. 3.4A). Cleavage of caspase-9 and caspase-3 was 
also detected in a similar temporal pattern (Fig. 3.4A). In addition, we quantified the 
activity of effector caspases (caspase-3/7) in the three cancer cells and found that the 
degree of activity (Fig. 3.4B) corresponded to that of apoptosis detected by sub-G1 
analysis (Fig. 3.3A). 
 
To confirm the involvement of the above-mentioned caspases, we utilized various 
synthetic caspase inhibitors to test their protective effects on I3M-induced cell death.  
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 Figure 3.1 Morphological changes and nuclear condensation of cancer cells in 
fluorescent microscope after DAPI staining. 
response to I3M treatment. HeLa (A), HepG2 (B), and HCT116 (C) were treated by 








Figure 3.2 Growth inhibitory effect of I3M on cancer cells. MTT reduction was 
observed in HeLa, HepG2 and HCT 116 in a dose-dependent manner when cells were 
treated by the indicated concentrations of I3M for 24 hr. Data are presented as means ± 




































B are presen nts.              
Fig .3        Time- and dose-dependent apoptosis in cancer cell lines. A. Tim
dependent responses to I3M treatment. The percentage of sub-G1 events in HeLa, 
HepG2 and HCT 116 cells treated with 20 μM I3M for the indicated time periods. 
Inserted are typical histograms derived from flow cytometry analysis of DNA content 
in control and I3M-treated HeLa cells (20 μM×24 hr). B. Dose-dependent responses to 
ent. The percentage of sub-G1 events in HeLa, HepG2 and HCT 116 cells 
were determined when treated with different concentrations of I3M for 24 hr. C.
induced PARP cleavage in HeLa cells determined by western blot. Data in panel 







Figure 3.4        I3M-induced caspase activation. A. I3M-induced caspase-8, -9 and -3 
cleavages in HeLa cells determined by western blot. B. I3M-induced caspase 3/7 
activity measured by Apo-OneTM Caspase-3/-7 Assay Kit. Three type of cancer cells 
were treated by 20 μM I3M for the indicated time periods. Data are presented as means 
± S.D. from at least three independent experiments.  
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Pretreatment with a pan caspase inhibitor (z-VAD) or a caspase-3 inhibitor (z-DEVD) 
completely protected I3M-induced apoptosis (Fig. 3.5). In contrast, pretreatment with 
a caspase-8 inhibitor (ac-IETD) or a caspase-9 inhibitor (ac-LEHD) only partially 
protected apoptosis induced by I3M (Fig. 3.5). Correspondingly, the pan caspase 
inhibitor (z-VAD) and the caspase-3 inhibitor (z-DEVD) suppressed the effector 
caspase activity to the basal level, whereas the caspase-8 and caspase-9 inhibitors (Ac-
IETD and Ac-LEHD) only partially inhibited the effector caspase activity (Fig. 3.6). 
Data from Fig. 3.4, Fig.3.5 and Fig. 3.6 collectively suggest that I3M-induced 
poptosis involves both the extrinsic and intrinsic apoptotic pathways.  
3.3 I3M induces increased surface expression of death receptors 
accompanying p53 up-regulation 
To provide a possible mechanism for the activation of the extrinsic pathway induced 
by I3M, we first evaluated the surface expression of the death receptor 4 and 5 (DR4 
and DR5) in HeLa cells. Upon treatment with I3M for 9 hr, levels of both receptors 
increased significantly (Fig. 3.7A). Such observations were confirmed by the total 
protein level of DR4 and DR5 determined by western blot (Fig. 3.7B). It has been 





suppressor gene p53 (Liu et al., 2004; Pistritto et al., 2007). Here we also observed a 
time-dependent increase (with a peak at 12 hr) of the p53 protein level in cells trea
with I3M (Fig. 3.7C). The concurrent increase of the p21 protein level indicated the 





Figure 3.5 Inhibition of I3M-induced apoptosis by synthetic caspase inhibitors. 
Protective effects of inhibitors were measured by percentage of sub-G1 events. HeLa 
cells were treated by 20 μM I3M together with 50 μM individual caspase inhibitor for 
24 hr. Each treatment is represented by a typical histogram showing the sub-G1 peak; 
and the inserted image showing the cell morphology under light microscopy. The 
numerical data indicates the percentage of sub-G1 cells. Data are presented as means ± 







Figure 3.6 Inhibition of I3M-induced caspase activation by synthetic caspase 
inhibitors. Caspase 3/7 activity was measured by Apo-OneTM Caspase-3/-7 Assay Kit. 
HeLa cells were treated with 20 μM I3M together with 50 μM individual caspase 


















Figure 3.7 I3M-induced enhanced surface expressions of DR4 and DR5. A. 
Surface expression of DR4 and DR5. Untreated HeLa cells (Ctrl) and HeLa cells upon 
9 hr of exposure to I3M (20 μM) were analyzed by FACS using PE-conjugated DR4 
and DR5 antibodies. Isotype-matched antibodies (Iso) were used to control for 
unspecific binding. B. Total protein level for DR4 and DR5 determined by western 
blot. The cells were treated with I3M as indicated. C. I3M-induced p53 and p21 
upregulation. HeLa cells were treated as indicated and protein levels were determined 









3.4 I3M causes Bid cleavage 
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he extrinsic death receptor pathway can initiate the mitochondrial amplification loop 
in type II cells by caspase-8 mediated Bid cleavage and subsequent translocation of 
tBid (truncated Bid) to the mitochondria (Li et al., 1998; Luo et al., 1998). In this 
study, since I3M-induced apoptosis involves both caspase-8 and -9 activation (Fig. 
3.4A), we thus examined whether I3M could induce Bid cleavage. I3M led to evident 
 cle pletely 
revented by a pan-caspase inhibitor (z-VAD) or a caspase-8 inhibitor (Ac-IETD) 
(Fig. 3.8B), in correspondence with the pattern of protection regarding cell death (Fig. 
3.5).  
In order to confirm the role of Bid in I3M-induced apoptosis, we managed to 
knockdown the Bid expression levels in HeLa cells using the siRNA technique. With 
transient transfection, about 20% of protection can be observed in cells transfected 
ith Bid
or Lami
induced by I3M as determined by sub-G1 analysis (Fig. 3.10B). Consistently, PARP 
cleavage was also partially salvaged comparing to the cells expressing the control 
vector (Fig. 3.10C). 
T
Bid avage in a time- and dose-dependent manner (Fig. 3.8A), which is com
p
w  SiRNA comparing to cells transfected with non-silencing (negative control) 
n A/C (positive control) siRNA (Fig. 3.9B); the suppression of Bid expression 
was proved by western blot (Fig. 3.9A). Furthermore, we established the stable Bid 
knockdown HeLa cells using the pSuper vector system (Fig. 3.10A). In HeLa cells 










Figure 3.8 Bid cleavage in response to caspase activation in I3M-induced 
apoptosis. A. I3M-induced Bid cleavage in a time- and dose-dependent manner in 
HeLa cells under the indicated treatment conditions. B. Caspase inhibitors blocked
I3M-induced Bid clea
 
vage. HeLa cells were treated with 20 μM I3M for 24 hr with the 






Figure 3.9 Protection conveyed by Bid siRNA transient transfection agains
induced apoptosis. A. Reduction of Bid protein level in HeLa cells transiently 
transfected with Bid siRNA; non-silencing siRNA (non-sil) was used as negative 
control and validated Lamin A/C siRNA as positive control. B. Protection against 
I3M-induced apoptosis in HeLa cells transfected with Bid si
t I3M-
RNA. Cells were treated 
with I3M (20 μM×24 hr) and apoptosis was measured by percentage of sub-G1 events. 

















Figure 3.10 Protection conveyed by Bid knockdown against I3M-induced apoptosis. 





I3M (20 μM×24 hr). PARP cleavage was determined as Fig. 3.3. 
 
Bid SiRNA vector in comparison to cells with the control vector. B. Protection against 
I3M-induced apoptosis in HeLa cells stably expressing Bid SiRNA. Cells were 
with I3M (20 μM×24 hr) and apoptosis was measured by percentage of sub-G1 eve
Data are presented as means ± S.D. from three independent experiments. Statistical
significance was analyzed by Student’s t-test (**: p < 0.01 when compared with the 
control group). C. Bid knockdown partially protected I3M-induced PARP cleavage. 




ain pro-apoptotic Bcl-2 
mily members, such as Bax and Bak, can be conformationally activated to form 
omo-multimers/complex in the mitochondrial membrane and thereby increase the 
membrane perm ational 




amount of transform unoprecipiation 
data in Fig. 3.11B that there is a time- and dose-dependent increase of Bax pulled 
suspected to be the dim
inhibitor (ac-IETD) significantly blocked such changes (Fig. 3.11C). Finally, Bid 
knockdown also significantly suppressed Bax conformational changes induced by I3M 




I3M induces Bax conformational changes 
In response to Bid or other BH3-only proteins, multi-dom
fa
h
eability (Tsujimoto, 2003). Here we investigated the conform
change of Bax using the following two methods: (i) immunofluorescence detected 
using a specific antibody (anti-Bax 6A7) that can recognize the N-term
d Bax (Hsu and Youle, 1998; Nechushtan et al., 1999), and (ii) 
immunoprecipiation and western blot. In I3M-treated HeLa cells, there is a tim
dose-dependent increase of red fluorescence (Fig. 3.11A), indicating the in
ed Bax. Such results are consistent with the imm
down by anti-Bax 6A7. Bands at about 42 kDa were observed in Fig. 3.11B and 
mer form of Bax. Furthermore, Bax conformational change 

























Figure 3.11 Bax conformational change following caspase-8 activation in I3M-
treated HeLa cells. A. Conformational changes of Bax detected by 
immunofluorescence staining and shown in red fluorescence. Cell nuclei were 
counterstained by DAPI. Representative images were captured under a confocal 
microscope. B. Conformational changes of Bax detected by immunoprecipitation (IP) 
and western blot (WB). Following designated treatments, transformed Bax was 
immunoprecipitated using anti-Bax 6A7 antibody and then subject to western blot 
analysis using anti-Bax N-20 antibody. C. Caspase-dependent Bax conformational 
change. HeLa cells were treated with I3M (20 μM) with the presence of caspase 
inhibitors (50 μM) for 24 hr and the transformed Bax was detected as in Panel A. D. 
Reduced Bax conformational change in HeLa cells stably expressing Bid siRNA. Cells 
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were treated with 20 μM I3M for 24 hr and the transformed Bax was detected as in 
Panel A. 
 62
3.6 I3M induces cytochrome c release 
Increased mitochondrial membrane permeability due to Bax-Bak complex formation 
can cause the release of cytochrome c and other apoptogenic factors from the 
mitochondrial intermembrane space, which would eventually stimulate caspase-9 and 
caspase-3 activation and execute apoptosis (Saelens et al., 2004). To furtherinvestigate 
I3M’s effect on mitochondria, we examined cytochrome c release from mitochondria. 
A time-dependent increase of cytochrome c in the cytosolic fraction was observed 
(Fig. 3.12). 
 
3.7 Overexpression of Bcl-2 or CrmA partially blocks I3M-induced apoptosis 
Data presented above highlight the critical role of the pro-apoptotic Bcl-2 family 
members in I3M-induced apoptosis at the site of mitochondria. Here we used genetic 
approaches to further examine the role of the anti-apoptotic Bcl-2 protein in I3M-
induced apoptosis. HeLa cells were transiently transfected with expression vector of 
either Bcl-2 protein or the viral protein cytokine response modifier A (CrmA), a 
known specific caspase-8 inhibitor (Miura et al., 1995), together with a green 
fluorescent protein (GFP) construct as a transfection marker. For a more reliable 
analysis of the effects of overexpressed Bcl-2 or CrmA on I3M-induced apoptosis, we 
analyzed the DNA content/sub-G1 profile only among the transfected cell population, 
indicated by the expression of GFP (Fig. 3.13A). Based on the morphological changes 
of transfected cells (with green fluorescence) (Fig. 3.13B) and flow cytometry analysis 
of those transfected cells (Fig. 3.13C), overexpression of CrmA or Bcl-2 provided 








Figure 3.12 I3M-induced cytochrome c release. HeLa cells were treated by 20 µM 
I3M for 0, 6, 12, 18 and 24 hr and subjected to subcellular fractionation to isolate 
cytosolic fractions. Protein levels were examined by western blot. Cox IV indicated 



















Figure 3.13 Ectopic expression of Bcl-2 or CrmA protects against I3M-induced 
apoptosis. A. HeLa cells were first transiently transfected with pcDNA empty vector, 
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Bcl-2, or CrmA expression vector, respectively, together with PmaxGFP as a 
transfection marker. After treatment, cells were collected and stained with PI for DNA 
content analysis. Among total of 20,000 cells from each group analyzed using flow 
cytometry, only those transfected cells with GFP expression and PI staining were 
presented for the analysis of sub-G1 events. B. Morphology of transiently transfected 
HeLa cells viewed under fluorescent microscope; 48 hr post transfection, cells were 
treated by I3M (20 μM×24 hr) as indicated. Successfully transfected cells were 
indicated by green fluorescence. C. Representative histograms from each transfection 
group with or without I3M treatment. D. Quantification of percentage of sub-G1 
events. Data are presented as means ± S.D. from three independent experiments. 
Statistical significance was analyzed by Student’s t-test (**: p < 0.01 when compared 
with the pcDNA group; *: p < 0.05). 
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3.8 I3M sensitizes cancer cells to TRAIL–induced apoptosis. 
It has been shown that I3M was able to sensitize TNF-induced apoptosis in human 
cancer cells (Sethi et al., 2006). Here we further assessed the effect of I3M on TRAI
induced cell death. First, we tested the cytotoxicity of TRAIL on human cancer cel
lines originated from various tissues, including human cervical cancer cells HeLa, 
human nasopharyngeal cancer cells CNE1, human live cancer cells HepG2, and human 
colorectal cancer cells HT29. Some cancer cells were reported to be TRAIL resi
(Shi et al., 2005). According to our data, up to as high as 200 ng/mL TRAIL induced 
less than 50% of apoptosis in CNE1, HepG2, or HT29 cells even after 24 hr treatm
(Fig. 3.14A), while the HeLa cells tested in this experiment were more sensitive t
TRAIL-induced apoptosis. When these cells were pretreated with I3M for 2 hr, 






ion of TRAIL for additional 6 hr, apoptosis in all 
our cell lines investigated increased, as measured by percentage of sub-G1 events, 
whereas I3M or TRAIL alone did not induce significant cell death (Fig. 3.14B). Fig. 
3.14C shows the chromatin condensation in HeLa cells treated with I3M and TRAIL. 
These data suggest that I3M pretreatment not only markedly sensitizes TRAIL-
resistant cancer cells but also significantly accelerates the cell death process. Long-
term effects of I3M and TRAIL were tested in these cancer cells using colony 
formation assay. I3M (10 µM) alone has a certain degree of growth inhibitory effects 
on HeLa cells in the long term (Fig. 3.14D) whereas it was not cytotoxic in the short-
term apoptosis assay (Fig. 3.14B). A combination of I3M and TRAIL completely 
suppressed HeLa cell growth and colony formation (Fig. 3.14D); similar results were 













Figure 3.14      I3M sensitizes human cancer cells to TRAIL-induced apoptosis. A. 
HeLa, CNE1, HepG2, and HT29 cells were treated with various concentrations of 
TRAIL for 24 hr. B. Cells were first pretreated with indicated concentrations of I3M 
for 2 hr, followed by treatment with a subtoxic concentration of TRAIL for another 6 
hr (0.5 ng/ml for HeLa, 1 ng/ml for CNE1, 5 ng/ml for HepG2 and H T29). A and B, 
at the end of treatment, apoptosis was measured by percentage of sub-G1 events. Data 
are presented as means ± S.D. from three independent experiments. C. Apoptotic 
morphologic changes in HeLa cells with combined treatment with I3M (10 µM×8 hr) 
and TRAIL (1 ng/ml×6 hr). Top, cells observed under a normal light microscope; 
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bottom, cells with DAPI staining under an inverted fluorescence microscope. D. 
Colony formation assay. HeLa cells were plated on six-well plates (5,000 cells/well) 
and treated with I3M alone (10 µM), TRAIL alone (1 ng/ml), or their combination for 







DISCUSSIONS AND CONCLUSIONS 
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Chapter 5 Discussions and conclusions 
Previous studies have demonstrated that indirubin and its derivatives are promising 
anti-cancer agents based on the following observations: (i) they are capable of 
selectively inducing apoptotic cell death in a wide spectrum of human cancer cells 
with minimal toxicity on normal cells (Kim et al., 2007; Nam et al., 2005; Perabo et 
al., 2006; Ribas et al., 2006); and (ii) in vivo study in rat model has proved their 
efficacy in arresting tumor growth (Kim et al., 2007). However, the molecular 
mechanisms underlying the apoptotic cell death induced by indirubin and its 
derivatives have not been fully elucidated. In this study we provide convincing 
evidence demonstrating that I3M-induced apoptosis engages the extrinsic death 
receptor pathway with a type I  pro-apoptotic bcl-2 family 
members Bid a  enhance 
TRAIL-induced apoptosis in human cancer cells. 
 
4.1 I3M induced apoptosis in HeLa, HepG2 and HCT116 
Growth inhibitory effects of indirubin have been proven in various human cancer cells 
with evidence pointing to apoptosis. In our study, observed chromatin condensation 
based on DAPI staining (Fig. 3.1), DNA fragmentation detected by flow cytometry 
(Fig. 3.3A & B), PARP cleavage (Fig. 3.3C), and caspase cleavage and activation (Fig. 
3.4) provide convincing evidence for the occurrence of apoptosis in HeLa, HepG2 and 
HCT116 cells. Among the three cell lines, HeLa is most sensitive to I3M whereas 
HCT116 is least. A previous study has shown that another colon carcinoma, Co12, is 
not sensitive to I3M with IC50 value greater than 100 µM (Lee et al., 2005), suggesting 
I-cell behavior in which the
nd Bax play a critical role. In addition, we prove I3M can
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that I3M is not suitable for the treatment of colon cancer although other indirubin 




 of cell 
 
 by 
.2 Apoptosis induced by I3M recruits extrinsic pathways with type II response 
onsible for the 
 is 
paniculata, has been shown to induce apoptosis in HepG2 cells via caspase-8 
 
Despite that most previous studies conclude that indirubins induce apoptosis in 
cells, necrosis has also been reported based on Annexin V and PI co-staining (Damiens
et al., 2001; Kagialis-Girard et al., 2007). Furthermore, Ribas et al. (2006) reported 
caspase-independent cell death induced by 7-substituted indirubins, which has a 
marginal inhibitory effect towards CDKs and GSK-3 comparing to other indiru
derivatives. Therefore the chemical structure of indirubins influences the type
death induced and the inhibition of CDKs and GSK-3 seems to contribute to the
engagement of the apoptotic pathway. In the present study, the cell death induced
I3M in HeLa cells can be completely protected by the pan caspase inhibitor z-VAD 
(Fig. 3.5), excluding the possibility of other forms of cell death. 
 
4
Although existing study suggests kinase inhibition might be resp
cytotoxic effect (Knockaert et al., 2004), the molecular targets of indirubins as well as 
signaling process upstream of apoptotic commitment are still unidentified. Our study
the first to prove the involvement of the extrinsic death receptor pathway in I3M-
induced apoptosis, as demonstrated by evident caspase-8 activation at early time points 
(Fig. 3.4B), and the protective effect of a synthetic caspase 8 inhibitor (Fig. 3.5), as 
well as overexpression of a viral caspase 8 inhibitor CrmA (Fig. 3.13). Similar 
mechanism of action has been reported for a number of other natural products. For 
example, andrographolide, an extract from a traditional herbal medicine Andrographis 
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activation (Zhou et al., 2006). Similarly, prodelphinidin B-2,3,3’-di-gallate from 
Myrica rubra (Kuo et al., 2004) and the water extract of Phyllanthus urinaria have 











Furthermore, we observed increased surface expressions, as well as total protein level, 
of both death receptor DR4 and DR5 in HeLa cells upon I3M treatment (Fig. 3.7A & 
B). DR4 and DR5, also known as TRAIL-R1 and TRAIL-R2, respectively, contain 
functional cytoplasmic DD motifs, which associate with FADD upon activation b
apoptotic signals such as TRAIL (Cretney et al., 2007; Takeda et al., 2007). FADD
contains the DED and is involved in the activation of caspase-8 (Voortman et al., 
2007). Therefore, increased surface expression of DR4 and DR5 observed in I3M
treated cells (Fig. 3.7A) might contribute to the caspase-8 activation observed in Fig. 
3.4A. Yet, we did not investigate the activation of TNFR1 or Fas in our current study
which can also lead to the activation of caspase-8.  
 
It has been reported that expression of DR4 or DR5 is transcriptionally regulated by 
p53 tumor suppressor gene (Liu et al., 2004; Pistritto et al., 2007). In this study, 
significantly elevated p53 and p21 protein level in I3M-treated cells (Fig. 3.7B) 
suggests the possibility that I3M promotes DR4 and DR5 expression via activation of 
p53. Although a number of previous studies have shown that HeLa cells are either
deficient (Ridgway et al., 1993) or with low expression level of p53 (Haupt et al., 
1995), it has also been reported that in HeLa cells p53 could be functionally up-
regulated as evidenced by the increase of the p21 protein (Micheau et al., 2001)
fact, treatment using other indirubin derivatives have been observed to up-regulate p
in human cancer cells (Lee et al., 2005; Ribas et al., 2006), implying a common 
mechanism in indirubin derivative-induced apoptosis. At present, it remains to
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further tested as how I3M induces p53 accumulation and activation, and whether 
p53 activation observed is responsible for the up-regulation of DR4 and DR5. 
 
Another possible mechanism by which I3M promotes death receptor-mediated 
apoptosis is through modulation of NF-κB activity. The anti-apoptotic function of NF-
κB has been well established via the transcriptional regulation of various anti-apopto
genes such as (c-FLIP, cIAP1/2, and Survivin ) (Micheau et al., 2001; Thome and 
Tschopp, 2001). Indirubin and its derivatives have been reported to inhibit the NF-κB 













(Sethi et al., 2006). In the study by Sethi and colleagues, I3M did not affect the bas
level of NF-κB transcriptional activity. It remains to be further studied whether I3M-
mediated caspase-8 activation is achieved via the suppression of the NF-κB signaling 
pathway. 
 
On the other hand, I3M-induced apoptosis in HeLa cells also exhibit a response typic
of type II cells. While the extrinsic pathway is not sufficient for the full activation of 
effector caspases, the intrinsic mitochondrial pathway as demonstrated by caspas
activation (Fig. 3.4A) and cytochrome c release (Fig. 3.12) is involved; the 
permeabilization of mitochondria (or the loss of MMP) is the critical step in apoptosis 
that leads to an irreversible apoptotic stage. In the current study, evidence has show
that Bid cleavage (Fig. 3.8A) downstream of caspase-8 activation (Fig. 3.8B) ha
contributed partially to the apoptosis induced by I3M (Fig. 3.10B); Yet, there is still
some doubt on how exactly the mitochondrial pathway is activated since blocking of 
the extrinsic pathway by synthetic caspase-8 inhibitor (Fig. 3.5), or even CrmA —
very specific caspase inhibitor (Fig. 3.13D), could not provide a complete protectio
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which should be achieved if the mitochondria received apoptotic signal solely from th
death receptor pathway. Therefore it is reasonable to believe some upstream ap
e 
optotic 
ignal works directly on mitochondria besides caspase-8 activation. Other pro-
brane 
ical role of pro-apoptotic Bcl-2 family members 




apoptotic signals converge on mitochondria to induce outer mitochondrial mem
permeabilization include ROS stress or p53-dependent tumor suppression. Taking p53 
as an example, on one hand, p53 can trigger apoptosis by inducing the expression of 
the BH3-only protein PUMA; on the other hand, p53 can act in a transcription-
independent manner through direct activation of Bax or Bak or through binding to and 
blocking Bcl-2 and Bcl-XL (Green and Kroemer, 2004). Therefore, it would be 
interesting to know if the up-regulation of p53 induced by I3M has any direct effects 




3.8A) acts downstream of caspase-8 activation (Fig. 3.8B) and mediates the 
transduction of apoptotic signal from the extrinsic pathway to the intrinsic pathway. 
Futhermore, Bax conformational change occurs as the consequences of caspase-8 
activation (Fig. 3.11C) and Bid cleavage (Fig. 3.11D) based on immunofluo
data using conformation-specific antibody 6A7. It is still not fully understood how the 
BH3-only proteins signal to the multi-domain members Bax and Bak, and together 
they increase the permeability of mitochondrial outer membrane (several hypothes
have been reviewed by Tsujimoto, 2003.). In addition to changes in Bid and Bax, the 
role of Bak is another crucial point worth studying although it was not investigated in 
our study; enhanced Bak protein level and oligomerization, as observed in 
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parthenolide-induced mitochondrial dysfunction (Zhang et al., 2004), can be a 
direction for a more detailed study. 
 
In addition to BH3-only proteins, the anti-apoptotic Bcl-2 family members are also 
known to modulate the pro-apoptotic activity of Bax through sequestrating Bax by the 
formation of heterodimers (Yi et al., 2003). In the present study, ectopic expression o
Bcl-2 protein only offered moderate protection against I3M-induced cell death (
3.13C & D). Bcl-2 alone may not be sufficient to salvage the activation of the intrinsic 




e-8 is not influenced by Bcl-2 overexpression. Hence 
e protective effect of Bcl-2 was not as significant as CrmA. Collectively these data 
-apoptotic Bcl-2 family 
 
optotic 
proteins (Fulda and Debatin, 2006). Therefore, anticancer agents that can sensitize 
L would have a better protective effec
they have differential affinities for the pro-apoptotic members. Moreover, direct 
activation of caspase-3 by caspas
th
suggest that the engagement of both the anti-apoptotic and pro
members at the site of mitochondria is a key factor of the type II response in I3M-
induced apoptosis of HeLa cells. 
 
4.4 Sensitization of TRAIL-induced apoptosis 
The sensitizing effect of I3M on TRAIL-induced apoptosis in cancer cells enhances 
the therapeutic potential of I3M. Base on our data (Fig. 3.14), I3M can significantly 
increase and dramatically expedite the apoptosis induced by TRAIL in HeLa, CNE1
and HepG2 cells, but was not so effective in HT29 cells. TRAIL has the unique 
property of inducing apoptosis in cancer cells but sparing normal cells. The resistance 
to TRAIL found in many cancer cells limited its clinical application, which might 
involve aberrant expression of surface death receptors or changes in anti-ap
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TRAIL-induced apoptosis work through either increased functionality of death 
receptors or inhibit the effectiveness of anti-apoptotic proteins. For example, Luteolin, 
 dietary flavonoid commonly found in some medicinal plants, sensitizes TRAIL-
d 
l lines: cervical cancer HeLa, hepatoma HepG2 and 
olon cancer HCT116. More importantly, we reveal the apoptotic mechanism of I3M 




induced apoptosis through down-regulation of XIAP (Shi et al., 2005). We have 
shown that I3M can increase the surface expression of DR4 and DR5 in HeLa cells 
(Fig. 3.7A), a process correlated to p53 up-regulation (Fig. 3.7C); therefore, the up-
regulation of death receptors induced by I3M reasonably contribute to the sensitizing 
effect on TRAIL-induced apoptosis, although the exact mechanism requires further 
study. Moreover, p53 is likely to play a critical role, since HT29, a p53 mutant cell line 
(Tao et al., 2007), was not significantly sensitized by I3M unless relatively high 
concentrations of I3M (20 µM) and TRAIL (5 ng/ml) were used (Fig. 3.14B).  
 
4.5 Conclusions 
In summary, data from this study provide systematic evidence for apoptosis induce
by I3M in three human cancer cel
c
in HeLa cells: extrinsic death receptor pathway acco
critical involvement of the pro-apoptotic Bcl-2 family members (Bid and Bax). In 
addition, I3M is found to be effective in sensitizing TRAIL-induced apoptosis in 
various cancer cells. Indirubin and its derivatives have been known for their potential
anti-tumor activities. Therefore understanding of such mechanisms provides the 
for future studies to expand the scope of their anti-cancer effects.  
 
4.6 Directions for future study 
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Based on the observations of our study that I3M promotes the DR4 and DR5 
expression and the sensitization effect of I3M on TRAIL-induced apoptosis in those 
TRAIL-resistant cancer cells, the major direction of future study would then be to 
answer the following questions: how I3M regulates p53, whether death receptor u
regulation is the result of p53 activation, whether the expression level of anti-apopto
proteins is influenced by I3M, and how these changes contribute to the enhanced 
apoptosis induced by TRAIL. Some details not investigated in our current study are 
also interesting aspects of future study, including whether TNFR1 or Fas is activated
in response to I3M treatment, whether p53 activation has any direct effects on 
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